Joint Corp Q3 net loss $716K; plans to refranchise majority of corporate clinics

JOINT Corp

2023-Q3 EPS reported $0.09 revenue$87,081,953

Revenue $29.5M (+11% YoY); net loss $0.05/sh vs income $0.05/sh in Q3 2022.
Operating loss $898K vs operating income $732K; Adj EBITDA $2.9M vs $3.1M.
System-wide sales +8% to $119.3M; comp sales flat; total clinics 914.
Board authorized plan to refranchise/sell majority of corporate-owned clinics.
Reaffirmed FY 2023 guidance: revenue $115-118M, Adj EBITDA $11-12.5M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

JOINT Corp reported the quarter ended September 30, 2023 results: revenue $29.5 million, net income net loss of $716,000, or $0.05 per share, EPS $0.05 per share. Guidance reaffirmed.

Period: the quarter ended September 30, 2023
Revenue: $29.5 million
Net income: net loss of $716,000, or $0.05 per share
EPS: $0.05 per share
Guidance: reaffirmed
Result: reported results

Exact text from the filing

of chiropractic clinics, reported its financial results for the quarter ended September 30, 2023. Financial Highlights: Q3 2023 Compared to Q3 2022 ● Grew revenue by 11% to $29.5 million. ● Reported operating loss of $898,000, compared to operating income of $732,000. ● Reported net loss of $716,000, including a loss on disposition or impairment related to

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

JOINT Corp filing history →

Source: SEC EDGAR

accession 0001171843-23-006953

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.